The Denver Post - - BUSINESS - — Den­ver Post wire ser­vices

McDon­ald’s is try­ing to mod­ern­ize its im­age by rolling out de­liv­ery and promis­ing fresh beef in Quar­ter Pounders. But for now, $1 so­das are help­ing get peo­ple in the door. The Illi­nois-based com­pany says do­mes­tic sales rose 3.9 per­cent at es­tab­lished lo­ca­tions dur­ing the sec­ond quar­ter.

Trump weighs Fed chair nom­i­na­tion.

Pres­i­dent Don­ald Trump says he’s con­sid­er­ing ei­ther re-nom­i­nat­ing Janet Yellen for a sec­ond term as Fed chair or re­plac­ing her with some­one else, pos­si­bly Gary Cohn, who leads his Na­tional Eco­nomic Coun­cil. Yellen, nom­i­nated by Pres­i­dent Barack Obama, was the first woman to lead the cen­tral bank. She has de­clined to say whether she wants to serve an­other term.

IRS sees big drop in iden­tity theft.

The IRS says it is see­ing a big drop in the num­ber of iden­tity theft vic­tims af­ter the agency teamed up with tax pre­par­ers to fight the prob­lem. IRS Com­mis­sioner John Kosk­i­nen said Tues­day that the num­ber of vic­tims was nearly cut in half last year, com­pared to the pre­vi­ous year. At the same time, he said, more busi­nesses are be­ing tar­geted. Thieves use stolen iden­ti­ties to try to ob­tain fraud­u­lent tax re­funds.

Repub­li­cans mov­ing to re­peal fi­nan­cial rule.

Con­tin­u­ing to tar­get gov­ern­ment reg­u­la­tions, a Repub­li­can-led House voted Tues­day to over­turn a rule that would let con­sumers join to­gether to sue their banks or credit card com­pa­nies rather than use an ar­bi­tra­tor to re­solve a dis­pute. The Con­sumer Fi­nan­cial Pro­tec­tion Bureau fi­nal­ized the rule just two weeks ago.

Cel­gene Corp. to pay $280M to set­tle cancer drug fraud suit.

A New Jersey phar­ma­ceu­ti­cal com­pany has agreed to pay $280 mil­lion to set­tle a fed­eral law­suit al­leg­ing it com­mit­ted fraud by pro­mot­ing a drug for lep­rosy and an­other ther­apy for un­ap­proved cancer treat­ments, fed­eral pros­e­cu­tors an­nounced Tues­day.

The agree­ment set­tled claims made in Los Angeles fed­eral court by a for­mer sales man­ager who said Cel­gene sub­mit­ted false claims to Medi­care and health care pro­grams in 28 states and Wash­ing­ton, D.C., which were all par­ties to the set­tle­ment.

While the two drugs were later ap­proved for lim­ited cancer treat­ments, the com­pany pro­moted them widely to doc­tors for mul­ti­ple kinds of cancer years in ad­vance of ap­provals, the law­suit said.

Blue Apron an­nounces lead­er­ship change.

Amid its lat­est stock strug­gles, Blue Apron an­nounced on Tues­day that it is re­vamp­ing its lead­er­ship team.

The home de­liv­ery mealkit com­pany said in a state­ment that co-founder Matthew Wa­diak would be step­ping down as chief op­er­at­ing of­fi­cer to be­come a se­nior ad­viser to Blue Apron.

“Matt Wa­diak has played an in­stru­men­tal role in driv­ing for­ward Blue Apron’s mis­sion to make in­cred­i­ble home cook­ing ac­ces­si­ble to ev­ery­one,” said Matt Salzberg, Blue Apron CEO said in the state­ment.

Tim Smith, the com­pany’s vice pres­i­dent of sup­ply chain, has been named se­nior vice pres­i­dent and gen­eral man­ager of con­sumer prod­ucts, a newly cre­ated role over­see­ing ef­forts to per­son­al­ize and ex­pand of­fer­ings for cus­tomers.

Since its ini­tial public of­fer­ing in late June, Blue Apron has strug­gled to gain mo­men­tum. Its shares opened at $10 on the New York Stock Ex­change and they have yet to fin­ish a day trad­ing above the same mark. On Wed­nes­day, Blue Apron’s stock fin­ished the day at $7.50.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.